ASTRACT The Kaiser Permanente (KP) NCORP Community Site is committed to the principle that including community providers and a diverse patient population is essential to advancing oncology research. The KP NCORP Community Site has decades of experience conducting cancer clinical trial, care delivery, and disparities research. During the first funding cycle, the KP NCORP Community Site brought the benefits of our racially and ethnically diverse membership, increased access/accrual to clinical trials, and conducted cancer care delivery research. The KP NCORP Community Site was exceptionally successful with both total and specific trial enrollment to studies with our affiliated research bases. In 2017, for example, the KP NCORP Community Site was the second-highest enrolling member of SWOG for total accrual and the highest for CTEP-funded, SWOG-credited trials. In addition, KP NCORP Community Site clinicians and population scientists served on numerous NCI and Research Base Steering, Scientific, and Working Group Committees, making important contributions to the NCORP research agenda. In the next funding cycle, we will continue to participate in this integrated national network of community organizations to increase the involvement of community oncologists, other medical specialists, and our patients. Continued participation in multi-institutional cancer control, prevention, and care delivery research, as well as quality-of-life studies embedded within treatment and imaging studies conducted under the NCORP and NCTN, will benefit the community at large. Our clinician and population scientists will continue to serve on NCI and Research Base committees and provide insight into clinical significance, identifying care disparities, and provide input on feasibility during protocol development. We will continue to recruit patients, including enrolling participants from underrepresented populations.

Public Health Relevance

As a member of NCORP?s integrated network of community organizations and research bases, the Kaiser Permanente (KP) NCORP Community Site will bring medical advances to the community at large by increasing clinical trial access and accrual to cancer control, prevention, symptom management, imaging, treatment, and cancer care delivery research. KP?s integrated health plan presents an ideal platform for accelerating the translation of findings into clinical practice.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
5UG1CA189821-07
Application #
10001450
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Parker, Bernard W
Project Start
2014-08-01
Project End
2025-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Kaiser Foundation Research Institute
Department
Type
DUNS #
150829349
City
Oakland
State
CA
Country
United States
Zip Code
94612
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Flaig, Thomas W; Plets, Melissa; Hussain, Maha H A et al. (2017) Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol 3:e170231
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Chen, Robert W; Li, Hongli; Bernstein, Steven H et al. (2017) RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol 176:759-769
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527

Showing the most recent 10 out of 12 publications